跳至主要内容
临床试验/JPRN-jRCTs031180338
JPRN-jRCTs031180338已完成2 期

The prospective study to evaluate the efficacy of the combination therapy of inhaled budesonide/formoterol fumarate, clarithromycin, and montelukast in AFO after allogeneic SCT - Chiba AFO-01 study

Sakaida Emiko0 个研究点目标入组 85 人开始时间: 2019年3月18日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
85

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 16age old 至 <= 70age old(—)
性别
All

入选标准

  • 1. The patient who receives the 1st allogeneic stem cell transplantation
  • 2. The patient who can examine the pulmonary function tests.
  • 3. PS (ECOG), 0-2
  • 4. The patient who has no exceptionable organ problems
  • 1) serum ALT/AST concentrations:150 IU/L and under
  • 2) total bilirubin: 3mg/dL and under
  • 3) CCr:40ml/min or over (by C-G)
  • 4) arterial blood oxygen saturation or SpO2 in room air:94% or over
  • 5. Written informed consent

排除标准

  • 1. Known history of intolerance or allergy to any triplet component.
  • 2. The patient who has past history of asthma and had attack within one year.
  • 3. The patient who has already been treated with the triplet combination.
  • 4. The patient who has active infection
  • 5. The patient who has mental disability requiring treatment
  • 6. The patient who has severe thromboembolism, including myocardial infarction, cerebral infarction, and cardiovascular complications.
  • 7. The patient who has uncontrollable diabetes mellitus and metabolic disease
  • 8. The patient who has other malignancy requiring anticancer treatment
  • 9. Pregnancy or nursing.
  • 10. At the time of enrollment as judged by the enrolling investigator would interfere
  • with the subjects ability to comply with the study requirements

研究者

发起方
Sakaida Emiko

相似试验